Luteolin ameliorates DSS-induced colitis in mice via suppressing macrophage activation and chemotaxis.

Liwei Xue,Xiaosheng Jin,Tingting Ji,Rongzhou Li, Xiaoju Zhuge,Fang Xu,Zijiao Quan,Haibin Tong,Weilai Yu

International immunopharmacology（2023）

引用 0|浏览9

暂无评分

摘要

Luteolin emerges as a promising lead compound for the clinical therapy of colitis by virtue of its ability to ameliorate DSS-induced colitis, antagonize IKKα/β, suppress NF-κB signaling, and impede macrophage activation and migration.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要